中国癌症防治杂志2026，Vol.18Issue(1)：1-11,11.DOI:10.3969/j.issn.1674-5671.2026.01.01
贝伐珠单抗治疗复发性呼吸道乳头状瘤病的专家共识(2026版)
Expert consensus on Bevacizumab treatment for recurrent respiratory papillomatosis(2026 Edition)
摘要
Abstract
Abnormal angiogenesis is an important pathological characteristic of recurrent respiratory papillomatosis(RRP).Bevacizumab,by blocking the vascular endothelial growth factor(VEGF)/vascular endothelial growth factor receptor(VEGFR)signaling pathway,promotes the normalization of aberrant angiogenesis and vascular permeability in RRP lesions.This action results in a reduction of lesion burden,prolonging the interval between surgical interventions,and improving airway-related symptoms.Multiple studies have confirmed the therapeutic efficacy of Bevacizumab in the treatment of RRP,with acceptable short-term adverse events.This consensus was developed by the writing group based on published clinical evidence on Bevacizumab in RRP and clinical practice.Through multiple rounds of expert deliberation,a unified set of recommendation was formulated to guide the rational and standardized application of Bevacizumab in relevant clinical departments in China,thereby improving the standardization of RRP diagnosis and treatment.关键词
复发性呼吸道乳头状瘤病/贝伐珠单抗/抗血管生成药物/专家共识Key words
Recurrent respiratory papillomatosis/Bevacizumab/Antiangiogenic drugs/Expert consensus分类
医药卫生引用本文复制引用
中国抗癌协会肺癌整合防筛专业委员会,山东省罕见疾病防治协会少见肿瘤分会,山东省医学会罕见疾病分会,朱栋元,肖洋,印明柱..贝伐珠单抗治疗复发性呼吸道乳头状瘤病的专家共识(2026版)[J].中国癌症防治杂志,2026,18(1):1-11,11.基金项目
创新药物和医疗器械临床研究与产品开发(CSTB2023TIAD-STX0011) （CSTB2023TIAD-STX0011）
